Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer

Xu, Xinzhi; Jin, Chunxiang; Zhang, Kai; Cao, Yang; Liu, Junjun; Zhang, Yue; Ran, Haitao; Jin, Ying

doi:10.1016/j.mtbio.2022.100245

Cited by 5 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, due to the difference in the oxidative environment and pH gradient within the tumor, the effect is obvious, and the combination of the two stimulations has also attracted much attention. Many research results have successfully codelivered chemotherapy drugs and RNA molecules and improved treatment efficacy. − …”

Section: Tme-based Stimuli-responsive Rna Delivery Systemsmentioning

confidence: 99%

Tumor Microenvironment Responsive RNA Drug Delivery Systems: Intelligent Platforms for Sophisticated Release

Wang,

Zhang,

Lai

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Cancer is a significant health concern, increasingly showing insensitivity to traditional treatments, highlighting the urgent need for safer and more practical treatment options. Ribonucleic acid (RNA) gene therapy drugs have demonstrated promising potential in preclinical and clinical trials for antitumor therapy by regulating tumor-related gene expression. However, RNA's poor membrane permeability and stability restrict its effectiveness in entering and being utilized in cells. An appropriate delivery system is crucial for achieving targeted tumor effects. The tumor microenvironment (TME), characterized by acidity, hypoxia, enzyme overexpression, elevated glutathione (GSH) concentration, and excessive reactive oxygen species (ROS), is essential for tumor survival. Furthermore, these distinctive features can also be harnessed to develop intelligent drug delivery systems. Various nanocarriers that respond to the TME have been designed for RNA drug delivery, showing the advantages of tumor targeting and low toxicity. This Review discusses the abnormal changes of components in TME, therapeutic RNAs' roles, underlying mechanisms, and the latest developments in utilizing vectors that respond to microenvironments for treating tumors. We hope it provides insight into creating and optimizing RNA delivery vectors to improve their effectiveness.

show abstract

Section: Tme-based Stimuli-responsive Rna Delivery Systemsmentioning

confidence: 99%

Tumor Microenvironment Responsive RNA Drug Delivery Systems: Intelligent Platforms for Sophisticated Release

Wang,

Zhang,

Lai

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…What is more, siRNA drugs‐induced transient genetic disruption could elicit controllable and durable therapeutic safety, rather than producing the risk of changing the genome of patients induced by shRNA‐mediated nucleic acids therapy and CRISPR‐Cas9 system‐mediated gene editing. Currently, siRNA therapy has been widely used in cancer treatment, with the representative applicational direction including inhibiting EMT, [ 148 ] inhibiting angiogenesis, [ 149 ] inhibiting invasion and metastasis, [ 150 ] enhancing chemotherapy sensitivity, [ 151 ] and immune therapy. [ 152 ] However, the undesirable stability induced by ubiquitous RNase in blood circulation and the potential off‐target effects are the deficiency that needed to be solved in siRNA drug therapeutic strategy.…”

Section: Nucleic Acid Drugs For Cancer Therapymentioning

confidence: 99%

Redox‐Responsive Polymeric Nanoparticle for Nucleic Acid Delivery and Cancer Therapy: Progress, Opportunities, and Challenges

Cao

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Cancer development and progression of cancer is closely associated with the activation of oncogenes and loss of tumor suppressor genes. Nucleic acid drugs (e.g., siRNA, mRNA, and DNA) have been widely used for cancer therapy due to their specific ability to regulate the expression of any cancer‐associated genes. However, nucleic acid drugs are negatively charged biomacromolecules that are susceptible to serum nucleases and could not cross cell membrane. Therefore, specific delivery tools are required to facilitate the intracellular delivery of nucleic acid drugs. In the past few decades, a variety of nanoparticles (NPs) have been designed and developed for nucleic acid delivery and cancer therapy. In particular, the polymeric NPs in response to the abnormal redox status in cancer cells have garnered much more attention as their potential in redox‐triggered nanostructure dissociation and rapid intracellular release of nucleic acid drugs. In this review, we briefly introduce the important genes or signaling pathways regulating the abnormal redox status in cancer cells and systemically summarize the recent development of redox‐responsive NPs for nucleic acid delivery and cancer therapy. We also discuss the future development of NPs‐mediated nucleic acid delivery and their challenges in clinical translation.This article is protected by copyright. All rights reserved

show abstract

“…Nowadays, cancer has gradually become a major disease which seriously threatens the health and life of humans. − As the traditional treatment, chemotherapy relies on toxic chemical groups to kill cancer cells and has been widely used for the therapy of tumor. − To improve therapeutic efficacy, various prodrugs have been developed to overcome the shortcomings (such as systemic toxicity, the lack of tumor selectivity, and poor solubility) of traditional chemotherapy. − Generally, the prodrugs can be activated by the tumor microenvironment (pH, , enzyme, etc.) or external stimuli (light, etc.).…”

Section: Introductionmentioning

confidence: 99%

Multifunctional Nanoplatform for Single NIR Laser-Regulated Efficient PDT/PTT/Chemotherapy

Chen,

Lu,

Wang

2024

Biomacromolecules

View full text Add to dashboard Cite

The combination of phototherapy and chemotherapy with superior advantages is a promising strategy for cancer therapy. However, combination therapy is generally regulated by two different wavelengths of light or other stimuli, which results in complex operations and inevitable systemic side effects, even affecting therapeutic efficacy. Herein, we design a signal NIR lightregulated nanoplatform via the self-assembly process of reactive oxygen species (ROS)-sensitive prodrug (DTD), human serum albumin (HSA), and IR780 for combined photothermal/photodynamic therapy and chemotherapy. Upon 808 nm laser irradiation, IR780 in nanoparticles generates abundant ROS and a significant photothermal effect to achieve photothermal/photodynamic therapy. Meanwhile, the generating ROS further cleans up the thioketal link to release DOX for chemotherapy. Hence, signal NIR light can effectively control the process of combination therapy. In vivo and in vitro experiment results demonstrate that the multifunctional nanoparticles exhibit excellent antitumor efficacy via the combination of phototherapy and chemotherapy controlled by a signal NIR laser. Overall, the signal NIR light-regulated nanoparticles with combination therapy performance provide a versatile platform for enhancing antitumor efficacy.

show abstract

Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer

Cited by 5 publications

References 81 publications

Tumor Microenvironment Responsive RNA Drug Delivery Systems: Intelligent Platforms for Sophisticated Release

Tumor Microenvironment Responsive RNA Drug Delivery Systems: Intelligent Platforms for Sophisticated Release

Redox‐Responsive Polymeric Nanoparticle for Nucleic Acid Delivery and Cancer Therapy: Progress, Opportunities, and Challenges

Multifunctional Nanoplatform for Single NIR Laser-Regulated Efficient PDT/PTT/Chemotherapy

Contact Info

Product

Resources

About